Your browser doesn't support javascript.
loading
Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.
Johnson, Fraser D; Ferrarone, John; Liu, Alvin; Brandstädter, Christina; Munuganti, Ravi; Farnsworth, Dylan A; Lu, Daniel; Luu, Jennifer; Sihota, Tianna; Jansen, Sophie; Nagelberg, Amy; Shi, Rocky; Forcina, Giovanni C; Zhang, Xu; Cheng, Grace S W; Spencer Miko, Sandra E; de Rappard-Yuswack, Georgia; Sorensen, Poul H; Dixon, Scott J; Guha, Udayan; Becker, Katja; Djaballah, Hakim; Somwar, Romel; Varmus, Harold; Morin, Gregg B; Lockwood, William W.
Afiliação
  • Johnson FD; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Ferrarone J; Meyer Cancer Centre, Weill Cornell Medicine, New York City, NY, USA.
  • Liu A; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Brandstädter C; Department of Biochemistry and Molecular Biology, Justus Liebig University Giessen, Giessen, Germany.
  • Munuganti R; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Farnsworth DA; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.
  • Lu D; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.
  • Luu J; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Sihota T; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Jansen S; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Nagelberg A; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Shi R; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.
  • Forcina GC; Department of Biology, Stanford University, Stanford, CA, USA.
  • Zhang X; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Cheng GSW; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Spencer Miko SE; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada.
  • de Rappard-Yuswack G; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Sorensen PH; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Dixon SJ; Department of Biology, Stanford University, Stanford, CA, USA.
  • Guha U; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Becker K; Department of Biochemistry and Molecular Biology, Justus Liebig University Giessen, Giessen, Germany.
  • Djaballah H; High Throughput Screening Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, NY, USA; Keren Therapeutics, New York City, NY, USA.
  • Somwar R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Varmus H; Meyer Cancer Centre, Weill Cornell Medicine, New York City, NY, USA.
  • Morin GB; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Lockwood WW; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic add
Cell Rep ; 38(6): 110343, 2022 02 08.
Article em En | MEDLINE | ID: mdl-35139387
ABSTRACT
Phenotype-based screening can identify small molecules that elicit a desired cellular response, but additional approaches are required to characterize their targets and mechanisms of action. Here, we show that a compound termed LCS3, which selectively impairs the growth of human lung adenocarcinoma (LUAD) cells, induces oxidative stress. To identify the target that mediates this effect, we use thermal proteome profiling (TPP) and uncover the disulfide reductases GSR and TXNRD1 as targets. We confirm through enzymatic assays that LCS3 inhibits disulfide reductase activity through a reversible, uncompetitive mechanism. Further, we demonstrate that LCS3-sensitive LUAD cells are sensitive to the synergistic inhibition of glutathione and thioredoxin pathways. Lastly, a genome-wide CRISPR knockout screen identifies NQO1 loss as a mechanism of LCS3 resistance. This work highlights the ability of TPP to uncover targets of small molecules identified by high-throughput screens and demonstrates the potential therapeutic utility of inhibiting disulfide reductases in LUAD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxirredutases / Tiorredoxina Dissulfeto Redutase / Estresse Oxidativo / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxirredutases / Tiorredoxina Dissulfeto Redutase / Estresse Oxidativo / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá